Navigation Links
Shire's Replenished Portfolio Drives Excellent Quarterly Performance

DUBLIN, April 29, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to March 31, 2010.

    Financial Highlights

                                                      Q1 2010(1)

    Product sales                                $718 million     -5%

    Product sales from core products(2)          $626 million    +36%

    Total revenues                               $816 million       -

    Non GAAP operating income                    $265 million    -19%

    US GAAP operating income                     $218 million     -4%
    Non GAAP diluted earnings per ADS                   $1.01    -21%
    US GAAP diluted earnings per ADS                    $0.89    -23%

    (1) Percentages compare to equivalent 2009 period.
    (2) Core products represent Shire's products excluding ADDERALL XR.
    Angus Russell, Chief Executive Officer, commented:

"This was an excellent first quarter performance with our core product sales up 36% and cash generation increasing 19% to $278 million. Despite the impact of authorised generic ADDERALL XR, total reported revenues in the quarter were at 2009 levels, reflecting our success in replenishing our portfolio with products providing strong growth and robust intellectual property. Across the business we saw significant developments: VYVANSE now has approximately a 14% share of the US ADHD market, our two recently launched products VPRIV and INTUNIV are performing well and in the EU REPLAGAL is now the leading Fabry treatment, with an estimated 60% market share.

We are investing in our growing int

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio
2. ClearTrial to Demonstrate How a Top 20 Sponsor Achieved -1 Percent Cost Variance Across Their $130M Clinical Portfolio at Major Industry Conference
3. EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets
4. New Industry Research Identifies "Operational Gap" in Clinical Trial Portfolio Management
5. Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma
6. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
7. The Pittsburgh Life Sciences Greenhouse Invests $725K in Portfolio Companies
8. Octapharma Aims to Expand U.S. Immune Globulin Therapy Portfolio
9. EUCODIS Bioscience Launches Lipase Portfolio
10. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
11. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015 The 2015 Nobel ... The University of Texas at Dallas. Aziz Sancar , ... Dallas in 1977, is one of three ... cells continuously monitor and repair damaged DNA on a molecular level.  ... molecular and cell biology from UT Dallas ...
(Date:10/8/2015)... , Oct. 8, 2015  Today the Wyss Institute ... launch of its start-up company Opsonix Inc. ... Harvard,s Office of Technology Development (OTD) and ... sepsis therapy for clinical use. ... least a million people every year in the U.S. ...
(Date:10/8/2015)... ... October 08, 2015 , ... Cystic ... transmembrane conductance regulator (CFTR) gene and results in dysfunction of the lungs and ... in the lungs. This mucus is very difficult to clear, blocks the airways ...
(Date:10/7/2015)... ... October 07, 2015 , ... ... will present a public educational seminar on the latest advances in adult stem ... 1:00 pm – 3:00 pm at the Hilton Dallas/Southlake Town Square in Southlake, ...
Breaking Biology Technology:
... Aug. 4 Elusys Therapeutics, Inc. ... been awarded a second contract year of funding valued at ... for the prevention and treatment of anthrax infection following a ... million already received under this contract and is part ...
... QUÉBEC CITY, Aug. 4 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: ... specialized in oncology and endocrinology, will announce its second quarter 2010 financial ... . The Company will host a conference call and webcast to discuss ... . , , , ...
... LOUIS , Aug. 3 K-V Pharmaceutical Company (NYSE: ... engaged BDO USA, LLP ("BDO") as the Company,s independent registered accounting firm. , ... The Company and BDO will ... 2010 Form 10-K and will then follow with the review of its quarterly ...
Cached Biology Technology:
(Date:9/9/2015)... , Sept. 9, 2015  NuData Security ... and solution-based milestones, furthering the company,s commitment to ... online fraud. NuData Security,s online fraud ... the company,s growth cycle. The product combines continual ... determine good user behavior from fraudulent behavior, allowing ...
(Date:9/2/2015)... 2015 Security of data and assets ... government organizations, telecommunications, hospitals, as well as individuals. ... being used to prevent unauthorised access. Technological advancements ... individuals could gain access to secure premises after ... hardware devices and numeric codes. However, hackers also ...
(Date:8/31/2015)... -- Research and Markets ( ) has announced ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Biomedical Sensors market is estimated at $0.23 billion by ... 2014-2020 The near future will bring biomedical ... each individual. These sensors can be set to trigger ...
Breaking Biology News(10 mins):
... They,re soft, biocompatible, about 7 millimeters long ... "bio-bots" developed at the University of Illinois are ... biological machines has been a riddle that scientists ... struggled to solve. The walking bio-bots demonstrate the ...
... Valley, NY. (Nov. 15, 2012) Two studies published ... (21:7), now freely available on-line at , ... a study carried out at Baylor University, researchers concerned ... pancreas preservation and islet isolation have found that low ...
... for BC,s troubled salmon populations A University ... British Columbia,s pink salmon populations, and the salmon farming industry ... from sea lice infestations., There has long been concern that ... to wild fish stock in surrounding waters. , The researchers ...
Cached Biology News:
... analysis & visualization software. ... multiple samples. Combine Sequest ... increased confidence. Get more ... from your MS/MS experiments.14 ...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Biology Products: